49,100 Shares in GSK plc (NYSE:GSK) Purchased by Harvest Portfolios Group Inc.

Harvest Portfolios Group Inc. acquired a new position in shares of GSK plc (NYSE:GSK - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 49,100 shares of the pharmaceutical company's stock, valued at approximately $2,007,000.

A number of other hedge funds have also recently added to or reduced their stakes in GSK. Primecap Management Co. CA grew its holdings in GSK by 13.9% during the 2nd quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company's stock worth $558,689,000 after acquiring an additional 1,773,020 shares during the last quarter. Mondrian Investment Partners LTD grew its holdings in GSK by 37.8% during the 1st quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company's stock worth $236,250,000 after acquiring an additional 1,512,442 shares during the last quarter. Acadian Asset Management LLC grew its holdings in GSK by 180.0% during the 1st quarter. Acadian Asset Management LLC now owns 2,219,798 shares of the pharmaceutical company's stock worth $95,129,000 after acquiring an additional 1,426,935 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in GSK during the 2nd quarter worth about $52,487,000. Finally, Kahn Brothers Group Inc. bought a new position in shares of GSK in the 1st quarter valued at about $53,743,000. Institutional investors own 15.74% of the company's stock.

Wall Street Analyst Weigh In

GSK has been the topic of several analyst reports. Barclays upgraded shares of GSK to a "hold" rating in a report on Tuesday, August 27th. Argus upgraded GSK to a "strong-buy" rating in a research report on Wednesday, August 7th. Finally, Guggenheim downgraded GSK from a "buy" rating to a "neutral" rating in a report on Thursday, October 31st. Five research analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $50.00.

GSK Trading Up 1.6 %

GSK traded up $0.59 during mid-day trading on Thursday, hitting $36.49. The stock had a trading volume of 11,596,812 shares, compared to its average volume of 3,957,713. The stock's fifty day simple moving average is $40.25 and its 200-day simple moving average is $40.97. The firm has a market capitalization of $75.63 billion, a price-to-earnings ratio of 23.31, a price-to-earnings-growth ratio of 1.42 and a beta of 0.66. GSK plc has a 1-year low of $33.89 and a 1-year high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be paid a dividend of $0.3928 per share. This represents a $1.57 annualized dividend and a yield of 4.31%. The ex-dividend date of this dividend is Friday, November 15th. This is an increase from GSK's previous quarterly dividend of $0.38. GSK's dividend payout ratio (DPR) is presently 100.00%.

Insider Buying and Selling at GSK

In other GSK news, major shareholder Plc Gsk acquired 2,791,930 shares of the business's stock in a transaction dated Friday, September 27th. The shares were acquired at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the acquisition, the insider now directly owns 16,775,691 shares of the company's stock, valued at approximately $134,205,528. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 10.00% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.